Branding, Cosmetics, Insulin and Licensing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Branding

Cosmetics

Insulin

Licensing

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

FEBRUARY 8, 2021

Like generic forms of synthetic pharmaceuticals, biosimilars have the advantage of being less costly compared to their branded counterparts. Some prescribers and pharmacists have been hesitant to give patients biosimilar forms of biologic drugs over concerns that they may not be as safe or effective as the branded product.

Production

Production Insulin Branding Generic Drugs

Comments on Notice of Proposed Rulemaking titled “Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796”

Pharmacy Checkers

MARCH 11, 2020

The FDA should be commended for its effort to create rules, pursuant to Section 804 of the Food, Drug and Cosmetic Act, that can lead to a regulated and safe channel of wholesale drug importation from Canada to help reduce cost burdens on states and consumers. counterparts.

Pharmacy

Pharmacy Drugs FDA Approval Licensing

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

Comments on Notice of Proposed Rulemaking titled “Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796”

Stay Connected